JAN 03, 2018 08:14 AM PST

Cancer Immunotherapy: Novel Innate Approaches

Immunotherapy for cancer treatment has been a major are of focus for the past several years, and it has proven effective in multiple cancer types.  Numerous studies are now looking at immunotherapies in combination with other traditional chemotherapy regimens, with personalized medicines, and with inhibitors of epigenetic modifiers.  All of this is great, and contributing to significant strides in the right direction for cancer research.  There are more than 1,000 combination trials harnessing the ability of the immune system to recognize and kill cancer cells, primarily through the use of checkpoint inhibitors or T-cell modification and expansion.  More recently, new evidence has been growing to show that there is another side to the immune system we can harness for therapeutic benefit.

While the current approach deals with the adaptive immune response where immune cells surveil their environment and react in response to certain antigen after identification and processing to arm an “attack” on the antigen’s host, there are new reports that the innate immune response, which is far less complex and more immediate, may also elicit a therapeutically beneficial response.  Major companies such as Merck, Novartis, and Bristol Myers Squibb have been investing in this approach with so far, good results.  The idea here is that so-called “cold” tumors, or those that are uninflamed and are not eliciting immune response at all, can be “heated” up.  The new innate immune response drug candidates are being investigated to work in combination with the current adaptive immune response therapeutics – so these new candidates are administered to initiate an immune response in an otherwise response-free tumor, and then once the immune cells have infiltrated the tumor, the adaptive response drugs can act to optimize the overall immune response waged on the tumor. 

These drugs which are aimed to elicit immune response are also being studied for other conditions aside from cancer, such as autoimmune diseases.  In cancer, they have already made it into Phase I clinical trials.  This new approach is very exciting and promising, and is making waves in the cancer research community.

Sources: Nature Reviews Drug Discovery, Wikipedia, Pixabay, Youtube, Aladdin Creations

 

About the Author
You May Also Like
JUL 04, 2018
Drug Discovery
JUL 04, 2018
First Drug Approved for The Treatment of Hyperhidrosis
Hyperhidrosis is a chronic skin condition that results in the increased production of sweat than needed. A certain amount of sweat is normally produced to ...
JUL 09, 2018
Cell & Molecular Biology
JUL 09, 2018
Scientists Found a New Way to Treat Lung Cancer
Small cell lung cancer is an aggressive type that can be fatal; there were few treatments for the disease. That may have changed....
JUL 31, 2018
Drug Discovery
JUL 31, 2018
DNA For Drug Development?
Genetic data of individuals who were customers of DNA testing service for the purpose of understanding their ancestry and genetic history, such as the comp...
AUG 21, 2018
Drug Discovery
AUG 21, 2018
Genetic Regulators of Regeneration Bring Hope for Drug Discovery
Portions of DNA that do not seem to have a function are referred to as “junk”. Now, according to a study published in Regenerative Medicine, re...
SEP 04, 2018
Drug Discovery
SEP 04, 2018
Cellular Mechanism Inspires Bone-Forming Drugs
There exists a certain amount of therapeutic drugs that treat osteoporosis by promoting bone formation in comparison to only a few drugs used to suppress b...
SEP 18, 2018
Drug Discovery
SEP 18, 2018
Compound Prevents Malaria Transmission in Mosquitoes
In a publication in Nature Communications, scientists from the Imperial College London have recently screened 70,000 compounds and were able to find just 6...
Loading Comments...